Journal article
Systemic Therapy for Melanoma: ASCO Guideline Update
R Seth, SS Agarwala, H Messersmith, KC Alluri, PA Ascierto, MB Atkins, K Bollin, M Chacon, N Davis, MB Faries, P Funchain, JS Gold, S Guild, DE Gyorki, V Kaur, NI Khushalani, JM Kirkwood, JL McQuade, MO Meyers, A Provenzano Show all
Journal of Clinical Oncology | Published : 2023
DOI: 10.1200/JCO.23.01136
Abstract
PURPOSETo provide guidance to clinicians regarding the use of systemic therapy for melanoma.METHODSAmerican Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature.RESULTSThe updated review identified 21 additional randomized trials.UPDATED RECOMMENDATIONSNeoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous melanoma. For patients with resected cutaneous melanoma, adjuvant nivolumab or pembrolizumab was newly recommended for stage IIB-C disease and adjuvant nivolumab plus ipilimumab was added as a potential option for stage IV disease. For patients with unresectable or metastatic cuta..
View full abstract